These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
225 related articles for article (PubMed ID: 33066597)
1. FGFR4 Inhibitor BLU9931 Attenuates Pancreatic Cancer Cell Proliferation and Invasion While Inducing Senescence: Evidence for Senolytic Therapy Potential in Pancreatic Cancer. Sasaki N; Gomi F; Yoshimura H; Yamamoto M; Matsuda Y; Michishita M; Hatakeyama H; Kawano Y; Toyoda M; Korc M; Ishiwata T Cancers (Basel); 2020 Oct; 12(10):. PubMed ID: 33066597 [TBL] [Abstract][Full Text] [Related]
2. First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway. Hagel M; Miduturu C; Sheets M; Rubin N; Weng W; Stransky N; Bifulco N; Kim JL; Hodous B; Brooijmans N; Shutes A; Winter C; Lengauer C; Kohl NE; Guzi T Cancer Discov; 2015 Apr; 5(4):424-37. PubMed ID: 25776529 [TBL] [Abstract][Full Text] [Related]
3. Overexpression of fibroblast growth factor receptor 4 in high-grade pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma. Motoda N; Matsuda Y; Onda M; Ishiwata T; Uchida E; Naito Z Int J Oncol; 2011 Jan; 38(1):133-43. PubMed ID: 21109934 [TBL] [Abstract][Full Text] [Related]
4. FGFR4 provides the conduit to facilitate FGF19 signaling in breast cancer progression. Zhao X; Xu F; Dominguez NP; Xiong Y; Xiong Z; Peng H; Shay C; Teng Y Mol Carcinog; 2018 Nov; 57(11):1616-1625. PubMed ID: 30074276 [TBL] [Abstract][Full Text] [Related]
5. Combination of FGFR4 inhibitor Blu9931 and 5-fluorouracil effects on the biological characteristics of colorectal cancer cells. Jiang D; Li J; Li J; Wang M; Han C; Wang X; Zhao C; Ye Y Int J Oncol; 2017 Nov; 51(5):1611-1620. PubMed ID: 29048661 [TBL] [Abstract][Full Text] [Related]
6. Implications of FGF19 on sorafenib-mediated nitric oxide production in hepatocellular carcinoma cells - a short report. Gao L; Shay C; Lv F; Wang X; Teng Y Cell Oncol (Dordr); 2018 Feb; 41(1):85-91. PubMed ID: 28983785 [TBL] [Abstract][Full Text] [Related]
7. Fibroblast Growth Factor 19-Mediated Up-regulation of SYR-Related High-Mobility Group Box 18 Promotes Hepatocellular Carcinoma Metastasis by Transactivating Fibroblast Growth Factor Receptor 4 and Fms-Related Tyrosine Kinase 4. Chen J; Du F; Dang Y; Li X; Qian M; Feng W; Qiao C; Fan D; Nie Y; Wu K; Xia L Hepatology; 2020 May; 71(5):1712-1731. PubMed ID: 31529503 [TBL] [Abstract][Full Text] [Related]
8. FGF19 and FGFR4 promotes the progression of gallbladder carcinoma in an autocrine pathway dependent on GPBAR1-cAMP-EGR1 axis. Chen T; Liu H; Liu Z; Li K; Qin R; Wang Y; Liu J; Li Z; Gao Q; Pan C; Yang F; Zhao W; Zhang Z; Xu Y Oncogene; 2021 Jul; 40(30):4941-4953. PubMed ID: 34163030 [TBL] [Abstract][Full Text] [Related]
9. Src is essential for the endosomal delivery of the FGFR4 signaling complex in hepatocellular carcinoma. Shin JY; Ahn SM J Transl Med; 2021 Apr; 19(1):138. PubMed ID: 33794926 [TBL] [Abstract][Full Text] [Related]
10. Fibroblast growth factor 19 is correlated with an unfavorable prognosis and promotes progression by activating fibroblast growth factor receptor 4 in advanced-stage serous ovarian cancer. Hu L; Cong L Oncol Rep; 2015 Nov; 34(5):2683-91. PubMed ID: 26323668 [TBL] [Abstract][Full Text] [Related]
11. Fibroblast growth factor receptor 4 increases epidermal growth factor receptor (EGFR) signaling by inducing amphiregulin expression and attenuates response to EGFR inhibitors in colon cancer. Hong CS; Sun EG; Choi JN; Kim DH; Kim JH; Ryu KH; Shim HJ; Hwang JE; Bae WK; Kim HR; Kim KK; Jung C; Chung IJ; Cho SH Cancer Sci; 2020 Sep; 111(9):3268-3278. PubMed ID: 32533590 [TBL] [Abstract][Full Text] [Related]
12. Fibroblast Growth Factor Receptor 4 Targeting in Cancer: New Insights into Mechanisms and Therapeutic Strategies. Lang L; Teng Y Cells; 2019 Jan; 8(1):. PubMed ID: 30634399 [TBL] [Abstract][Full Text] [Related]
13. Fibroblast growth factor receptor 4 (FGFR4) and fibroblast growth factor 19 (FGF19) autocrine enhance breast cancer cells survival. Tiong KH; Tan BS; Choo HL; Chung FF; Hii LW; Tan SH; Khor NT; Wong SF; See SJ; Tan YF; Rosli R; Cheong SK; Leong CO Oncotarget; 2016 Sep; 7(36):57633-57650. PubMed ID: 27192118 [TBL] [Abstract][Full Text] [Related]
14. HMGA1 induces FGF19 to drive pancreatic carcinogenesis and stroma formation. Chia L; Wang B; Kim JH; Luo LZ; Shuai S; Herrera I; Chen SY; Li L; Xian L; Huso T; Heydarian M; Reddy K; Sung WJ; Ishiyama S; Guo G; Jaffee E; Zheng L; Cope LM; Gabrielson K; Wood L; Resar L J Clin Invest; 2023 Mar; 133(6):. PubMed ID: 36919699 [TBL] [Abstract][Full Text] [Related]
15. Dissecting the Role of the FGF19-FGFR4 Signaling Pathway in Cancer Development and Progression. Liu Y; Cao M; Cai Y; Li X; Zhao C; Cui R Front Cell Dev Biol; 2020; 8():95. PubMed ID: 32154250 [TBL] [Abstract][Full Text] [Related]
16. FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib. Gao L; Wang X; Tang Y; Huang S; Hu CA; Teng Y J Exp Clin Cancer Res; 2017 Jan; 36(1):8. PubMed ID: 28069043 [TBL] [Abstract][Full Text] [Related]
17. Fibroblast growth factor receptor type 4 as a potential therapeutic target in clear cell renal cell carcinoma. Narisawa T; Naito S; Ito H; Ichiyanagi O; Sakurai T; Kato T; Tsuchiya N BMC Cancer; 2023 Feb; 23(1):170. PubMed ID: 36803783 [TBL] [Abstract][Full Text] [Related]
18. Interrupting the FGF19-FGFR4 Axis to Therapeutically Disrupt Cancer Progression. Lang L; Shull AY; Teng Y Curr Cancer Drug Targets; 2019; 19(1):17-25. PubMed ID: 29557750 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of fibroblast growth factor 19 reduces tumor growth by modulating beta-catenin signaling. Pai R; Dunlap D; Qing J; Mohtashemi I; Hotzel K; French DM Cancer Res; 2008 Jul; 68(13):5086-95. PubMed ID: 18593907 [TBL] [Abstract][Full Text] [Related]
20. FGF19 Is Coamplified With CCND1 to Promote Proliferation in Lung Squamous Cell Carcinoma and Their Combined Inhibition Shows Improved Efficacy. Zhang Y; Wu T; Li F; Cheng Y; Han Q; Lu X; Lu S; Xia W Front Oncol; 2022; 12():846744. PubMed ID: 35463335 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]